Abstract

In antibody directed enzyme prodrug therapy (ADEPT) an antibody bound enzyme is targeted to tumor cells. This allows for selective activation of a nontoxic prodrug to a cytotoxic agent at the tumor site for cancer therapy. Site-selective prodrug activation results in reduced side effects in remote tissue. This article reviews ADEPT with emphasis on the chemical viewpoint and recent developments.

Keywords: Antibody Directed Enzyme Prodrug Therapy, ADEPT, Anticancer Therapy, Alkaline Phosphatase, Amino Peptidases, Aryl Sulfatase, Carboxylesterase, Carboxypeptidase A, Carboxypeptidase G2 (CpG2), Cytosine Deaminase